MENU
+Compare
MNPR
Stock ticker: NASDAQ
AS OF
Jan 15, 04:59 PM (EDT)
Price
$69.26
Change
-$0.34 (-0.49%)
Capitalization
466.38M

MNPR Monopar Therapeutics Inc Forecast, Technical & Fundamental Analysis

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients... Show more

MNPR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for MNPR with price predictions
Jan 14, 2026

MNPR in +7.03% Uptrend, advancing for three consecutive days on January 14, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MNPR advanced for three days, in of 254 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MNPR's RSI Oscillator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 13, 2026. You may want to consider a long position or call options on MNPR as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MNPR just turned positive on January 12, 2026. Looking at past instances where MNPR's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

MNPR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MNPR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for MNPR entered a downward trend on January 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.295) is normal, around the industry mean (27.929). P/E Ratio (0.000) is within average values for comparable stocks, (51.397). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.899). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.547).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MNPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
MNPR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company, which engages in building a drug development pipeline of oncology therapeutics in late preclinical and clinical development stages

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1000 Skokie Boulevard
Phone
+1 847 388-0349
Employees
10
Web
https://www.monopartx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DLBMX17.410.07
+0.40%
MassMutual Small Cap Opps A
PDIAX22.140.03
+0.14%
Virtus KAR Equity Income A
FOPTX21.37N/A
N/A
Fidelity Advisor Intl Sm Cap Opps M
FIKMX12.18N/A
N/A
Fidelity Advisor Real Estate Income Z
ZIFIX10.04-0.05
-0.50%
American Beacon Ninety One Int Frn R5

MNPR and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MNPR has been loosely correlated with QNCX. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if MNPR jumps, then QNCX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNPR
1D Price
Change %
MNPR100%
+3.82%
QNCX - MNPR
35%
Loosely correlated
N/A
KURA - MNPR
33%
Loosely correlated
+1.63%
XNCR - MNPR
33%
Poorly correlated
+3.66%
ROIV - MNPR
32%
Poorly correlated
+1.58%
PTCT - MNPR
32%
Poorly correlated
+2.51%
More